Liraglutide
As of the edition of 20 October 2026, Liraglutide is a protein: marketed, first approved in 2009 (EU); acts on GLP1R; US protection ended in 2025.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Protein
- Brand name
- Victoza
- First approved
- 30 June 2009 (EU)
- Approvals on record
- 21 in 6 regions
- Holder of the most recent approval
- Stada Arzneimittel; 6 holders in all
- Registered trials
- 315, 24 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Immune system; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health
US protection
US protection ended in 2025.
The last listed US drug-substance patent ended in 2025. The application that gives this date is held by Novo Nordisk.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | P43220 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 56 | 41 | 3 | 4 |
| Phase 1 | 65 | 57 | 1 | 3 |
| Phase 2 | 39 | 24 | 3 | 6 |
| Phase 3 | 76 | 64 | 2 | 2 |
| Phase 4 | 79 | 49 | 9 | 9 |
| All trials | 315 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novo Nordisk | Applicant and Lead sponsor of trials | 1999 to now |
| Stada Arzneimittel | Later holder | 2026 to now |